YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)
Guidant Pacemakers
Guidant Pacemakers
2005 Recall
Guidant Corp. informed doctors about a new round of safety problems with its implantable heart devices. Guidant, recently recalled many of its heart devices because of safety concerns, said as of July 11, 2005; it had identified 69 of its older pacemakers that may have failed. Approximately 78,000 of the devices were distributed, and close to 28,000 remain implanted in patients. Guidant said the devices have not been sold or implanted for the past four years.
The problem involves a hermetic sealing component that may degrade over time, resulting in higher-than-normal moisture within the pacemaker that could cause "serious health complications. The U.S. Food and Drug Administration may classify this action a recall, Guidant said. Although no failures have been reported prior to 44 months of service, the likelihood increases with time. Guidant's modeling predicts the rate of failure in the remaining implanted devices to be between 0.17% and 0.51% over the rest of the device's life.
The pacemaker brand names involved are Pulsar, Pulsar Max, Discovery, Meridian, Pulsar Max II, Discovery II, Virtus Plus II, Intelis II, and Contak TR. Guidant recommended that physicians consider replacing the devices for pacemaker-dependent patients, and it advised patients to seek medical attention immediately if they notice shortness of breath, dizziness, lightheadedness or a prolonged fast heart rate. Guidant has confirmed 20 reports of loss of pacing output, including five patients experiencing syncope (temporary loss of consciousness and posture).
Loss of pacing output has also been associated with reports of presyncope (lightheadedness), requiring hospitalization. Additionally, Guidant has two reports of sustained maximum sensor rate pacing in which heart failure may have developed. In one report, a patient whose device exhibited sustained MSR pacing was admitted to the hospital with multiple health issues and later died.
2006 Recall
On June 26, 2005, Guidant in conjunction with the FDA notified patients and medical professional that the INSIGNIA and NEXUS implantable pacemakers and the Guidant CONTAK RENEWAL TR/TR2 Cardiac Resynchronization Therapy Pacemakers have been linked to five reports of device malfunction due to the failure of a low-voltage capacitor from a single component supplier. Individuals with these pacemakers may suffer irregular or permanent loss of output, telemetry, and or premature battery depletion.
If you or a loved one suffered injuries from a Guidant Pacemaker, please fill out the form at the right for a free case evaluation by a qualified defective medical device attorney.
Guidant Corp. informed doctors about a new round of safety problems with its implantable heart devices. Guidant, recently recalled many of its heart devices because of safety concerns, said as of July 11, 2005; it had identified 69 of its older pacemakers that may have failed. Approximately 78,000 of the devices were distributed, and close to 28,000 remain implanted in patients. Guidant said the devices have not been sold or implanted for the past four years.
The problem involves a hermetic sealing component that may degrade over time, resulting in higher-than-normal moisture within the pacemaker that could cause "serious health complications. The U.S. Food and Drug Administration may classify this action a recall, Guidant said. Although no failures have been reported prior to 44 months of service, the likelihood increases with time. Guidant's modeling predicts the rate of failure in the remaining implanted devices to be between 0.17% and 0.51% over the rest of the device's life.
The pacemaker brand names involved are Pulsar, Pulsar Max, Discovery, Meridian, Pulsar Max II, Discovery II, Virtus Plus II, Intelis II, and Contak TR. Guidant recommended that physicians consider replacing the devices for pacemaker-dependent patients, and it advised patients to seek medical attention immediately if they notice shortness of breath, dizziness, lightheadedness or a prolonged fast heart rate. Guidant has confirmed 20 reports of loss of pacing output, including five patients experiencing syncope (temporary loss of consciousness and posture).
Loss of pacing output has also been associated with reports of presyncope (lightheadedness), requiring hospitalization. Additionally, Guidant has two reports of sustained maximum sensor rate pacing in which heart failure may have developed. In one report, a patient whose device exhibited sustained MSR pacing was admitted to the hospital with multiple health issues and later died.
2006 Recall
On June 26, 2005, Guidant in conjunction with the FDA notified patients and medical professional that the INSIGNIA and NEXUS implantable pacemakers and the Guidant CONTAK RENEWAL TR/TR2 Cardiac Resynchronization Therapy Pacemakers have been linked to five reports of device malfunction due to the failure of a low-voltage capacitor from a single component supplier. Individuals with these pacemakers may suffer irregular or permanent loss of output, telemetry, and or premature battery depletion.
If you or a loved one suffered injuries from a Guidant Pacemaker, please fill out the form at the right for a free case evaluation by a qualified defective medical device attorney.
Guidant PacemakersRSS Feed
Defective Guidant Defibrillators Continue to Haunt Boston Scientific
Sep 11, 2006 | Newsinferno.com
According to recent SEC filings, Boston Scientific Corp. now faces about 477 individual and 72 class-action lawsuits over recalled Guidant defibrillators. Boston Scientific purchased Guidant earlier this year for $27 billion, after outbidding Johnson & Johnson. Both companies pursued Guidant even though the company had just recalled thousands of defibrillators and pacemakers. J&J’s decision not to match the higher offer appears to have been fortuitous, as Boston Scientific...
FDA Update Statement On Boston Scientific/Guidant Pacemakers And Defibrillators
Jul 17, 2006 | www.medicalnewstoday.co
The FDA met last week with Boston Scientific/Guidant to discuss the firm's recent announcement that several models of pacemakers and implantable defibrillators should be removed from hospital inventories because they have the potential to malfunction due to failure of the capacitor, which controls how the device holds its power supply. FDA fully supports the company's recommendation that physicians perform follow-up exams of patients with devices that may be susceptible to this malfunction....
Boston Scientific Announces Physician Communication Related to Products in Its CRM Group
Jun 26, 2006 | www.fda.gov
Contact: Paul Donovan 508-650-8541 Boston Scientific Corporation (NYSE: BSX) today announced that it is providing safety information and retrieving a specific subset of pacemakers, cardiac resynchronization pacemakers and implantable cardioverter defibrillators from its sales force and hospital inventories. The specific subset of devices includes INSIGNIA and NEXUS pacemakers, CONTAK RENEWAL TR/TR2 cardiac resynchronization pacemakers, and VENTAK PRIZM 2, VITALITY, and VITALITY 2 implantable...
Studies show implanted heart device can malfunction, but removal's risky
Apr 26, 2006 | Washington Post
Implantable defibrillators, which can deliver a life-saving shock to people with damaged hearts, have had a roller-coaster record of reliability, as the rate of malfunctions fell in the early years, rose in the late 1990s and recently declined again. Compared with pacemakers, which are simpler and serve a different purpose, implantable defibrillators are five to 20 times more likely to malfunction and need replacement. At the same time, people who learn that the device implanted in their...
Replacing Heart Device Found Risky
Apr 26, 2006 | Los Angeles Times
Surgery to replace potentially defective heart defibrillators carries an unexpectedly high rate of serious complications, including death, according to a study published today. The research in the Journal of the American Medical Assn. showed that one in 50 patients needed to have the replacement device removed because of severe postoperative infections. Dr. Andrew D. Krahn of Canada's University of Western Ontario and one of the study's authors said the overall complication rate was three...
Guidant Pacemakers
Quick Facts
Guidant Pacemakers Reference Guide
Manufacturer
Guidant Corporation
Status
Recall 2005
Recall 6/26/06
Approved Uses
Slow heart rates or rhythms
Loss of consciousness
Loss of posture
Lightheadedness
Hospitalization
Heart failure
Death Related Topics
Guidant Implantable Pacemakers
Medtronic Pacemakers
Defective Medical Devices
News Feeds
WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS
